Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jan 23;11(2):817-832.
doi: 10.18632/aging.101784.

Can ovarian aging be delayed by pharmacological strategies?

Jinjin Zhang  1 , Qian Chen  1 , Dingfu Du  1 , Tong Wu  1 , Jingyi Wen  1 , Meng Wu  1 , Yan Zhang  1 , Wei Yan  1 , Su Zhou  1 , Yan Li  1 , Yan Jin  1 , Aiyue Luo  1 , Shixuan Wang  1
Affiliations
Review

Can ovarian aging be delayed by pharmacological strategies?

Jinjin Zhang et al. Aging (Albany NY). .

Abstract

Aging has been regarded as a treatable condition, and delaying aging could prevent some diseases. Ovarian aging, a special type of organ senescence, is the earliest-aging organ, as ovaries exhibit an accelerated rate of aging with characteristics of gradual declines in ovarian follicle quantity and quality since birth, compared to other organs. Ovarian aging is considered as the pacemaker of female body aging, which drives the aging of multiple organs of the body. Hence, anti-ovarian aging has become a research topic broadly interesting to both biomedical scientists and pharmaceutical industry. A marked progress has been made in exploration of possible anti-ovarian agents or approaches, such as calorie restriction mimetics, antioxidants, autophagy inducers etc., over the past years. This review is attempted to discuss recent advances in the area of anti-ovarian aging pharmacology and to offer new insights into our better understanding of molecular mechanisms underlying ovarian aging, which might be informative for future prevention and treatment of ovarian aging and its related diseases.

Keywords: organ senescence; ovarian aging; pacemaker; pharmacological strategies.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST: The authors have no conflicts of interest.

Figures

Figure 1
Figure 1
Classification of anti-ovarian aging drugs. Some drugs may have several pharmacological actions.
See this image and copyright information in PMC

References

    1. Fontana L, Kennedy BK, Longo VD, Seals D, Melov S. Medical research: treat ageing. Nature. 2014; 511:405–07. 10.1038/511405a - DOI - PubMed
    1. Steel N, Ford JA, Newton JN, Davis AC, Vos T, Naghavi M, Glenn S, Hughes A, Dalton AM, Stockton D, Humphreys C, Dallat M, Schmidt J, et al. Changes in health in the countries of the UK and 150 English Local Authority areas 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2018; 392:1647–61. 10.1016/S0140-6736(18)32207-4 - DOI - PMC - PubMed
    1. Check Hayden E, and E CH. Anti-ageing pill pushed as bona fide drug. Nature. 2015; 522:265–66. 10.1038/522265a - DOI - PubMed
    1. Younis JS. Ovarian aging and implications for fertility female health. Minerva Endocrinol. 2012; 37:41–57. - PubMed
    1. Laisk T, Tšuiko O, Jatsenko T, Hõrak P, Otala M, Lahdenperä M, Lummaa V, Tuuri T, Salumets A, Tapanainen JS. Demographic and evolutionary trends in ovarian function and aging. Hum Reprod Update. 2018. 10.1093/humupd/dmy031 - DOI - PubMed

Publication types